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Electron density is REFMAC maximum-likelihood/σA-weighted 2 Fo−Fc synthesis contoured at 0.48 electrons per Å 3 . Table S1 . Apparent IC50 values of α-configured cyclophellitol azridrines 1-6 and epoxide 7 JJB307 on rGBA, determined in vitro. JJB343 (cyclophellitol-β-gluco-aziridine-BODIPY) was included for comparison. Data were average values of two separate experiments measured in duplicate, error ranges depict standard deviation. 
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Experimental methods Biological assays: Materials
Chemicals were obtained from Sigma-Aldrich, if not otherwise indicated. Trypsin and Endoproteinase GluC were commercially available from Promega. Recombinant GAA was obtained from Genzyme (Cambridge, MA, USA). Fibroblasts were obtained with consent from donors. Pompe patients were diagnosed on the basis of reduced GAA activity. Cell lines were cultured in HAMF12-DMEM medium (Invitrogen) supplied with 10% (v/v) FCS. Mouse tissue were isolated according to guidelines approved by the ethical committee of Leiden University (DEC#13191). All the cell or tissue lysates were prepared in potassium phosphate lysis buffer(25 mM in pH 6.5, supplemented with protease inhibitor 1x cocktail (Roche)) via homogenization with silent crusher S equipped with Typ 7 F/S head (30 rpm x 1000, 3 × 7 sec) on ice and lysate concentration was determined with BCA Protein Assay Kit (Pierce   TM   ) . The protein fractions were stored in small aliquots at -80 °C until use.
Enzyme activity assays and IC50 measurements.
The α-D-glucosidase activity of lysosomal α-D-glucosidase GAA was assayed at 37 °C by incubating with 3 mM 4-methylumbelliferyl-α-D-glucopyranoside as substrate in 150 mM McIlvaine buffer, pH 5.0, supplemented with 0.1% (w/v) BSA. Activity of rGBA was measured using similar conditions but with 3.75 mM 4-methylumbelliferyl-β-D-glucopyranoside as substrate at pH 5.2, supplemented with 0.1% (v/v) Triton X-100 and 0.2% (w/v) sodium taurocholate. To determine the apparent in vitro IC50 value, recombinant GAA or rGBA was firstly pre-incubated with a range of inhibitor dilutions for 30 min at 37 °C, prior to addition of the substrate. To determine the influence of pH on the enzymatic activity, enzyme mixtures were firstly pre-incubated for 30 min on ice with McIlvaine buffers of pH 2.0−8.0 whereafter substrate was added, dissolved in Nanopure H2O. The enzymatic reaction was quenched by adding excess NaOH-glycine (pH 10.3), after which fluorescence of liberated 4-methylumbelliferyl was measured with a fluorimeter LS55 (Perkin Elmer) using λEX 366 nm and λEM 445 nm. The in situ IC50 value was determined by incubating fibroblast cell lines expressing wild-type GAA, grown to confluence, with a range of inhibitor dilutions for 2 h. Hereafter, cells were washed three times with PBS and subsequently harvested by scraping in potassium phosphate buffer (25 mM K2HPO4-KH2PO4, pH 6.5, supplemented with 0.1% (v/v) Triton X-100 and protease inhibitor cocktail (Roche)). Residual GAA activity was measured using the aforementioned substrate assay. All in situ IC50 values were determined by replicating each assay twice in duplo in two separate cell lines. Data was corrected for background fluorescence, then normalized to the untreated control condition and finally curve-fitted via one phase exponential decay function (GraphPad Prism 5.0). 1 ABP 7 pull-down and LC-MS/MS analysis 3mg total protein from human fibroblast lysate or 6 mg total protein from mouse intestines lysate was incubated with either 0.1% (v/v) DMSO, 5 μM 7 JJB384, or firstly with 5 μM 3 JJB382 followed by 5 μM 6 JJB384. For mouse liver lysate, 6 mg total protein and 10μM ABPs 3 and 6 were used. Each step taking 30 min at 37 °C, in a total volume of 0.5 mL McIlvaine buffer of pH 4.0 and pH 7.0, subsequently denatured through the addition of 10% (w/v) SDS 125 μL and boiling for 5 min at 100 °C. From here on, samples were prepared for pull-down with streptavidin beads as published earlier 2 . After pull-down procedure, the samples were divided, 2/3 for on-bead digestion and 1/3 for in-gel digestion. On-bead digestion samples including beads were treated by the trypsin digestion buffer (a mixture containing 100 mM Tris-HCl pH 7.8, 100 mM NaCl, 1 mM CaCl2, 2% acetonitrile and 10 ng/μL trypsin) and the bead suspension was incubated in a shaker at 37 °C overnight. The supernatant containing the trypsin-digested peptides was desalted using stage tips, followed by evaporation of MeCN and dilution in 70 μL sample solution (H2O/MeCN/TFA, 95/3/0.1, v/v/v) for LC-MS analysis. The beads containing active-site peptides were treated with endoproteinase Glu-C digestion buffer (100ng/μL in PBS solution); incubated in a shaker at 37 °C overnight after which the supernatant was desalted using stage tips and for LC-MS. In-gel digestion samples were eluted by boiling the beads at 100 °C in 30 μL of 1x Laemmli buffer. The eluted proteins were separated on 10% protein gels at 200 V for 1 h, and the protein gels were silver stained using the Invitrogen kit, 2 and visualized by Bio-rad Chemi-Doc MP Imager using the silver stain channel. Bands were excised with a surgery knife by hand and treated with in-gel digestion buffer (10 mM NH4HCO3, 5% ACN, 1mM CaCl2, 10 ng/μL trypsin). The supernatant containing the trypsin-digested peptides was desalted using Stage Tips and prepared for LC-MS. All the peptide samples were analyzed with a 2h gradient of 5-25% ACN on nano-LC, hyphenated to an LTQ-Orbitrap and identified via the Mascot protein search engine, and the Raw data was calculated by MaxQuant program against the Uniprot human or mouse proteome database to present the protein identification list. 2 Mascot identifications were manually validated. The identification results were exported as Excel file including protein accession numbers, Mascot peptide scores, mass of the protein, % coverage of the protein by amino acids identified by LC-MS, peptide matches, miss cleavages, C-terminal peptides and protein emPAI values (see Supporting Information Data of Excel in compressed archive file(.zip)).
SDS-PAGE analysis and fluorescence scanning
For labeling procedures see below. All the labeling samples were pre-incubated in 150 mM McIlvaine buffer on ice for 5 minutes. Electrophoresis was performed with sodium dodecylsulfate containing 10% polyacrylamide gels. Wet slab-gels were then scanned for ABP-emitted fluorescence using a Bio-rad ChemiDoc MP imager using green Cy2 (λEX 470 nm, bandpass 30 nm; λEM 530 nm, bandpass 28) for 3 JJB382, red Cy3 (λEX 530 nm, bandpass 28 nm; λEM 605 nm, bandpass 50) for 4 JJB347, and blue Cy5 In vitro labeling of GAA The detection limit of each ABP was analyzed by labeling 1 pmol rGAA with 1,000−0.01 fmol 3 JJB382 in 150 mM McIlvaine buffer, pH 5.0, for 30 min at 37 °C. Influence of pH on ABP labeling involved pre-incubation of either 100 fmol rGAA or 10 μg murine liver lysate at pH 2−8 for 30 min on ice, prior to addition of 1 μM 3 JJB382, dissolved in Nanopure H2O and incubating for 30 min at 37 °C. Assessment of 3 JJB382 labeling kinetics involved pre-cooling of 100 fmol rGAA on ice for 15 min, followed by addition of similarly cooled 100 nM 3 JJB382 solution. After mixing, 3 JJB382 labeling was chased for 0−60 min at either 4 °C or 37 °C, whereafter labeling was stopped by denaturation. For competitive ABPP on rGAA, 1 pmol rGAA was pre-incubated with inhibitors (100 μM 7 JJB307, 1 Chris021, 2 Chris022, 10 μM 4 JJB347, 5 JJB383 or 6 JJB384, 10 mM 4MU-α-D-glucopyranoside, 2.5 M maltose) for 30 min at 37 °C, or boiled for 4 min in 2% (w/v) SDS, prior to labeling with 1 μM 3 JJB382 for 30 min at 37 °C. Labeling of human fibroblast lysates was performed on 100 μg total protein, using Visualizing pulled-down proteins by fluorescent detection and Western Blot. After pull-down of mouse intestinal enzymes using 6 JJB384, the supernatants and eluents (20 μL from both) of all treatment conditions (DMSO, competition, and JJB384, under pH 4.0 or pH 7.0) were subjected to SDS-PAGE and fluorescent detection (Bio-rad ChemiDoc MP Imager; Cy2 channel).
Proteins were subsequently transferred to PVDF membranes using a Trans-Blot® Turbo system (BioRad), blocked in 4% (w/v) BSA in TBST, and detected for biotin 6 JJB384 binding with Streptavidin-HRP antibody (Dako) .The blot was developed in the dark using a 10 mL luminal solution, 100 µL ECL enhancer and 3 µL 10% H2O2 solution. Chemiluminescence was visualized using the same ChemiDoc imager (BioRad).
Pompe GAA detection by Western blot.
Following fluorescent scanning of SDS-PAGE, proteins on wet slab gel were transferred to PVDF membrane and blocked as described in the previous section. For GAA detection, the membrane was incubated firstly with mouse polyclonal anti GAA and subsequently with goat anti mouse Alexa647 (Life Technologies). Blot was scanned on a Typhoon FLA 9500 Imager (GE Healthcare) using 633 nm laser and LPR filter, and 100 mm as pixel size. Rabbit anti β-actin (Cell Signaling) and goat anti rabbit Alexa647 (Invitrogen) were used for loading control.
In situ labeling of GAA Fibroblasts were treated with 5 JJB383 (100 nM, for 10 to 240 min) in culture medium. After washing 3 times with PBS, cells were harvested in potassium phosphate buffer (25 mM K2HPO4-KH2PO4, pH 6.5, supplemented with 0.1% (v/v) Triton X-100 and protease inhibitor cocktail (Roche)), prepared with or without 10 μM 3 JJB382. 20 μg total protein from each cell homogenate of the lysate was subjected to SDS-PAGE. Labeling were visualized by fluorescent detection using Bio-rad ChemiDoc MP Imager under the channels Cy5 for 5 JJB383 and Cy2 for 3 JJB382 with the above described settings. For Chloroquine treatment experiment, cultured fibroblasts were incubated with chloroquine (10-50 μM, for up to 3 h) and subsequently with 6 JJB383 (100 nM, for 3 h) in medium. Cells were harvested with or without 10 mM 3 JJB382 with the above describe methods. Homogenates were denatured, resolved on SDS-PAGE and detected for 5 JJB383 labeling by fluorescent scanning.
Agd31B expression and 3-D crystallography
Agd31B expression and purification was carried out as previously described. 3 Protein crystals were obtained using 1.8 M ammonium sulfate, 0.1 M HEPES [7.0] , 2% PEG 400 at 20 °C by the sitting drop vapor diffusion method. Crystal complexes with 1 CF021 and 2 CF022 were obtained by soaking in mother liquor containing 5 mM probe for 2 h, before cyroprotecting in 2.0 M lithium sulfate, 0.1 M HEPES [7.0] , 2% PEG 400, and flash freezing in liquid N2 for data collection (Table S2 ).
All data were collected at beamline I04 of the Diamond Light Source, processed using XDS 4 and reduced using Aimless. 5 Complex structures were solved by molecular replacement using MolRep, 6 before subsequent rounds of manual model building and refinement using Coot 7 and REFMAC5 8 respectively. Refinements were carried out using TLS determination of molecular motions. 9 Ligand coordinates were built using jLigand. 10 Crystal structure figures were generated using ccp4mg. equipped with a C18 column (Gemini, 4.6 mm x 50 mm, 3 μm particle size, Phenomenex) equipped with buffers A: H2O, B: acetonitrile (MeCN) and C: 1% aqueous TFA, For reversed-phase HPLC purifications an Agilent Technologies 1200 series instrument equipped with a semi preparative Gemini C18 column (10 x 250 mm) was used. The applied buffers were A: 50 mM NH4HCO3 in H2O, B:
MeCN.
(1R,2R,3S,6R)-6-(Hydroxymethyl)-cyclohex-4-ene-1,2,3-triol
The starting material diol 8 was prepared according to previously reported procedure. 12 Diol compound 8 (680 mg, 2.0 mmol, 1.0 eq.) was co-evaporated 3 times with toluene and then dissolved in dry THF (25 mL) and cooled to -60°C under argon atmosphere. Ammonia (20 mL) was condensed at -60°C under argon atmosphere. Lithium (207 mg, 30.0 mmol, 15 eq.) was added and the mixture was stirred until lithium was completely dissolved. To this solution was slowly added the solution of 8 in THF. The reaction mixture was stirred for 30 min at -60 °C and then quenched by adding of H2O (30mL). The resulting solution was allowed to come to room temperature and stirred until all ammonia had evolved. Next, the solution was concentrated in vacuo, redissolved in H2O, and neutralized with Amberlite IR-120 H + . Then, the filtration mixture was concentrated in vacuo and purified via silica gel column chromatography (10%→20% MeOH in DCM), affording colorless oil product (180 mg, 1.13 mmol, 57% (1R,6R,7R,8R,9S,10R)-10-Hydroxy-7-iodo-3-phenyl-12-trichloromethyl-13-aza-2,4,11-trioxatricyclo[7. 
4.4.0-8.4.3.0]tridec-12-ene (11)
A solution of 9 (535 mg, 2.15 mmol, 1 eq.) in dry DCM (60 mL) was made under argon atmosphere and cooled to 0 °C. DBU (64.4 µL, 0.431 mmol, 0.2 eq) and trichloroacetonitrile (216 µL, 10.77 mmol, 5 eq.) was added to the solution. After 3 hours, more trichloroacetonitrile (108 µL, 5.39 mmol, 2.5 eq.) was added to the reaction mixture. Starting material was fully conversed to imidate 10 with higher running spot on TLC after 21 hours stirring at room temperature.
Then iodine (1.70 g, 6 .68 mmol, 3.1 eq), NaHCO3 (1.81 g, 21.5 mmol, 10 eq.) and water (3.8 mL) was added to the reaction mixture. After 26 hours of the first addition of the iodine and NaHCO3, iodine (1.70 g, 6 .68 mmol, 3.1 eq.) and NaHCO3 (1.81 g, 21.5 mmol, 10 eq.) was added to the reaction mixture. After approximately 96 hours after the first addition of iodine and NaHCO3, the reaction was quenched by adding Na2S2O3 (10% aqueous solution) until the purple color had disappeared. The reaction mixture was separated out and the DCM layer was concentrated in vacuo, redissolved in EtOAc and washed with water and brine. The initial aqueous layer was extracted with EtOAc and the combined organic layers were dried (MgSO4), filtered and concentrated in vacuo. The product was purified via silica gel column chromatography (0%→16% EtOAc in pentane) affording 11 (455 mg, 0.877 mmol, 41%) was produced. TLC (PE:EtOAc, 4/1, v/v) 90, 148.49, 147.88, 142.18, 132.57, 123.36, 122.60, 75.74, 73.34, 72.41, 63.50, 62.19, 51.20, 46.86, 45.99, 41.93, 32.23, 31.24, 30.83, 30.42, 29.88, 29.05, 28.22, 27.32, 25.87, 16.48, 14.44 (1S,2S,3S,4R,5R,6S)-7-(8-(4-(4-(5,5-difluoro-3,7-bis(4-methoxyphenyl) 20, 158.79, 148.60, 146.78, 137.49, 132.16, 132.14, 132.12, 128.42, 126.51, 123.24, 121.03, 114.85, 114.63, 75.75, 73.36, 72.46, 63.53, 62.18, 55.83, 51.24, 46.86, 45.97, 41.92, 34.13, 31.23, 30.98, 30.40, 30.33, 29.87, 28.20, 27.33, 25.78 1-(8-((1S,2S,3S,4R,5R,6S) and lyophilized resulting as dark blue powder product 5 (10.4 mg, 11.7 μmol, 23%) .
3,3-dimethyl-1-(6-oxo-6-(((
1 H NMR (600 MHz, CD3OD): δ ppm 2H), 7.84 (s, 1H), 2H), 7.41 (m, 2H), 4H), 6.62 (t, J = 12.4 Hz, 1H), 2H), 4.41 (s, 2H), 4.36 (t, J = 7.1 Hz, 2H), 4.09 (t, J = 7.5 Hz, 2H), 3.86 (dd, J = 10.7, 3.9 Hz, 1H), 5H), 1H), 47, 175.73, 175.38, 174.59, 155.54, 155.47, 146.13, 144.23, 143.53, 142.61, 142.51, 129.77, 129.73, 126.60, 126.27, 126.21, 124.15, 123.41, 123.28, 112.01, 111.84, 104.41, 104.23, 75.72, 73.31, 72.39, 63.48, 62.17, 51.33, 50.53, 50.50, 46.87, 46.00, 44.74, 41.92, 36.46, 35.56, 31.50, 31.30, 30.44, 30.41, 29.94, 28.25, 28.12, 27.93, 27.78, 27.37, 27.30, 26.39 146.22, 124.16, 75.74, 73.34, 72.41, 63.50, 63.38, 62.20, 61.62, 57.02, 51.35, 46.89, 46.01, 41.95, 41.05, 40.18, 36.81, 36.75, 35.58, 31.29, 30.45, 30.12, 29.95, 29.78, 29.50, 28.26, 27.54, 27.37, 26.93 A solution of compound 9 (100 mg, 0.40 mmol, 1 eq.) and 3-Chloroperbenzoic acid (mCPBA, 75%) (135 mg, 0.60 mmol, 1.5 eq) in dry DCM (10 mL) were made under argon atmosphere and refluxed at 40°C for 24h. The reaction mixture was washed by saturated NaHCO3 aqueous and brine. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The product was purified via silica gel column chromatography (50%→100% EtOAc in pentane), affording the title compound 17 (47 mg, 0.178 mmol, 44%). TLC (pentane:EtOAc, 3/1, v/v): Rf = 0.30; 1 H NMR (400 MHz, CDCl3): δ ppm 2H), 3H), 5.48 (s, 1H), 4.38 (dd, J = 12.0, 4.0 Hz, 1H), 1H), 1H), 1H), 2H) 
